

IMMUNOGEN INC  
Form 8-K  
December 11, 2006

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): December 11, 2006

**ImmunoGen, Inc.**

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other  
jurisdiction of  
incorporation)

**0-17999**  
(Commission File  
Number)

**04-2726691**  
(IRS Employer  
Identification No.)

**128 Sidney Street, Cambridge, MA 02139**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (617) 995-2500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-



**ITEM 8.01 - OTHER EVENTS**

On December 11, 2006, ImmunoGen, Inc. (Nasdaq: IMGN) issued a press release to announce the presentation of initial findings from a Phase I study evaluating the Company's huN901-DM1 TAP compound for the treatment of multiple myeloma at the annual meeting of the American Society of Hematology (ASH) in Orlando, FL. This Phase I study is designed to evaluate huN901-DM1 for the treatment of relapsed multiple myeloma. To qualify for enrollment, patients must have relapsed or relapsed/refractory multiple myeloma that expresses the CD56-antigen targeted by huN901-DM1; approximately 70% of multiple myeloma cases express this antigen. The initial findings show evidence of anticancer activity among the three patients receiving the higher of the two huN901-DM1 dose levels evaluated to date.

ImmunoGen also disclosed progress with the TAP compound, AVE9633, which is in development by sanofi-aventis for the treatment of acute myeloid leukemia (AML). The favorable tolerability profile of AVE9633 demonstrated in this first trial enables the compound to be evaluated in additional Phase I studies with a more frequent dosing schedule better suited to the highly proliferative nature of AML. A second Phase I study is underway in Europe.

The Company's TAP technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS**

| Exhibit No. | Exhibit  |
|-------------|--|
| 99.1        | Press Release of ImmunoGen, Inc. dated December 11, 2006 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ImmunoGen, Inc.**  
(Registrant)

Date: December 11, 2006

/s/ Daniel M. Junius

Daniel M. Junius  
Executive Vice President and Chief Financial Officer

**EXHIBIT INDEX**

| Exhibit No. | Exhibit  |
|-------------|--|
| 99.1        | Press Release of ImmunoGen, Inc. dated December 11, 2006 |

